Cyclophosphamide following Targeted Oral Busulfan as Conditioning for Hematopoietic Cell Transplantation: Pharmacokinetics, Liver Toxicity, and Mortality

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 7, 2007, Pages 853-862

  McCune, Jeannine S ^a,c   Batchelder, Ami ^a   Deeg, H Joachim ^a,b   Gooley, Ted ^a   Cole, Scott ^a   Phillips, Brian ^a   Schoch, H Gary ^a   McDonald, George B ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Busulfan; Cyclophosphamide; Diphenylhydantoin; Hematopoietic cell transplant; Mortality; Myeloablative regimen; Pharmacokinetics; Sinusoidal obstruction syndrome; Survival

Indexed keywords

AMPHOTERICIN; BUSULFAN; CARBOXYETHYLPHOSPHORAMIDE MUSTARD; CASPOFUNGIN; CYCLOPHOSPHAMIDE; DRUG METABOLITE; FLUCONAZOLE; HYDROXYCYCLOPHOSPHAMIDE; ITRACONAZOLE; MESNA; PHENYTOIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG METABOLISM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER DISEASE; LIVER TOXICITY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RELAPSE; SEIZURE; STATISTICAL SIGNIFICANCE; STEADY STATE; SURVIVAL; WHOLE BODY RADIATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BUSULFAN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; SURVIVAL RATE; SYNDROME; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 34250206633     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.03.012     Document Type: Article

References (63)

1. Santos G.W. Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation. Bone Marrow Transplant 4 Suppl 1 (1989) 236-239
2. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16 (1995) 31-42
3. Grochow L.B. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20 (1993) 18-25
4. Dix S.P., Wingard J.R., Mullins R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17 (1996) 225-230
5. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89 (1997) 3055-3060
6. Radich J.P., Gooley T., Bensinger W., et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102 (2003) 31-35
7. DeLeve L.D., and Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 60 (2000) 143-154
8. McCune J.S., Gibbs J.P., and Slattery J.T. Plasma concentration monitoring of busulfan: does it improve clinical outcome?. Clin Pharmacokinet 39 (2000) 155-165
9. Kashyap A., Wingard J., Cagnoni P., et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 8 (2002) 493-500
10. Lee J.H., Choi S.J., Lee J.H., et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 84 (2005) 321-330
11. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002) 1201-1207
12. Deeg H.J., Storer B.E., Boeckh M., et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 12 (2006) 573-584
13. Williams C.B., Day S.D., Reed M.D., et al. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant 10 (2004) 614-623
14. DeLeve L.D. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 24 (1996) 830-837
15. McDonald G.B., Slattery J.T., Bouvier M.E., et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 101 (2003) 2043-2048
16. Gibbs J.P., Gooley T., Corneau B., et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 93 (1999) 4436-4440
17. Andersson B.S., Kashyap A., Gian V., et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (i.v. BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8 (2002) 145-154
18. Slattery J.T., Kalhorn T.F., McDonald G.B., et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 14 (1996) 1484-1494
19. Petersdorf E.W. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol 11 (2004) 386-391
20. Petersdorf E.W., Anasetti C., and Martin P.J. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 104 (2004) 2976-2980
21. Marr K.A., Leisenring W., Crippa F., et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 103 (2004) 1557-1559
22. Kalhorn T.F., Howald W.N., Cole S., et al. Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 835 (2006) 105-113
23. McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118 (1993) 255-267
24. Yule S.M., Boddy A.V., Cole M., et al. Cyclophosphamide metabolism in children. Cancer Res 55 (1995) 803-809
25. Yule S.M., Boddy A.V., Cole M., et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 41 (1996) 13-19
26. Yule S.M., Price L., Cole M., Pearson A.D., and Boddy A.V. Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemother Pharmacol 47 (2001) 222-228
27. Yule S.M., Price L., McMahon A.D., Pearson A.D., and Boddy A.V. Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma. Clin Cancer Res 10 (2004) 455-460
28. Tasso M.J., Boddy A.V., Price L., Wyllie R.A., Pearson A.D., and Idle J.R. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol 30 (1992) 207-211
29. Qiu R., Yao A., Vicini P., et al. Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard. Clin Pharmacol Ther 76 (2004) 270-280
30. Yule S.M., Walker D., Cole M., et al. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Dispos 27 (1999) 417-421
31. Yule S.M., Walker D., Pearson A.D., and Idle J.R. Potential inhibition of alkylating agent metabolism by fluconazole. Eur J Clin Microbiol Infect Dis 13 (1994) 1086-1087
32. de Jonge M.E., Huitema A.D., Rodenhuis S., and Beijnen J.H. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44 (2005) 1135-1164
33. Hassan M., Ljungman P., Ringden O., et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 25 (2000) 915-924
34. Anderson G.D. A Mechanistic Approach to Antiepileptic Drug Interactions (2004), Marcel Dekker, Inc, New York
35. Potschka H., Fedrowitz M., and Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 306 (2003) 124-131
36. Huang Z., Roy P., and Waxman D.J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59 (2000) 961-972
37. Ren S., Yang J.S., Kalhorn T.F., and Slattery J.T. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 57 (1997) 4229-4235
38. Qiu R., Kalhorn T.F., and Slattery J.T. ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat. J Pharmacol Exp Ther 308 (2004) 1204-1212
39. Faucette S.R., Wang H., Hamilton G.A., et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 32 (2004) 348-358
40. de Jonge M.E., Huitema A.D., van Dam S.M., Beijnen J.H., and Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol 55 (2005) 507-510
41. Chen T.L., Passos-Coelho J.L., Noe D.A., et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 55 (1995) 810-816
42. Sladek N.E., Doeden D., Powers J.F., and Krivit W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 68 (1984) 1247-1254
43. Geraci J.P., Mariano M.S., and Jackson K.L. Radiation hepatology of the rat: microvascular fibrosis and enhancement of liver dysfunction by diet and drugs. Radiat Res 129 (1992) 322-332
44. Tutschka P.J., Copelan E.A., and Klein J.P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70 (1987) 1382-1388
45. Lichtman S.M., Ratain M.J., Van Echo D.A., et al. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a cancer and leukemia group B study. J Natl Cancer Inst 85 (1993) 1319-1326
46. Brodsky R.A., Sensenbrenner L.L., Smith B.D., et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 135 (2001) 477-483
47. Akay H., Akay T., Secilmis S., Kocak Z., and Donderici O. Hepatotoxicity after low-dose cyclophosphamide therapy. South Med J 99 (2006) 1399-1400
48. Mok C.C., Wong W.M., Shek T.W., Ho C.T., Lau C.S., and Lai C.L. Cumulative hepatotoxicity induced by continuous low-dose cyclophosphamide therapy. Am J Gastroenterol 95 (2000) 845-846
49. Goldberg J.W., and Lidsky M.D. Cyclophosphamide-associated hepatotoxicity. South Med J 78 (1985) 222-223
50. Peters W.P., Henner W.D., Grochow L.B., et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 47 (1987) 6402-6406
51. Ayash L.J., Wright J.E., Tretyakov O., et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 10 (1992) 995-1000
52. Petros W.P., Broadwater G., Berry D., et al. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res 8 (2002) 698-705
53. Nieto Y., Cagnoni P.J., Bearman S.I., Shpall E.J., Matthes S., and Jones R.B. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (Stamp-I) for Breast cancer. Biol Blood Marrow Transplant 6 (2000) 198-203
54. Grochow L.B., Jones R.J., Brundrett R.B., et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25 (1989) 55-61
55. Hassan M., Oberg G., and Ljungman P. Correlation between hepatic veno-occlusive disease (VOD) and busulphan levels using limited sampling model for dose estimation. Blood (1997) 251a
56. Kashyap A., Synold T., Parker P., O'Donnell M.R., Nademanee A., and Forman S.J. First dose area under the curve (AUC) of oral busulfan predicts risk of developing veno-occlusive diseases (VOD) in adult allogeneic bone marrow tranplant (BMT) patients. Proc ASCO 16 (1997) 215a
57. Pawlowska A.B., Blazar B.R., Angelucci E., Baronciani D., Shu X.O., and Bostrom B. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 20 (1997) 915-920
58. Poonkuzhali B., Srivastava A., Quernin M.H., et al. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 24 (1999) 5-11
59. Nilsson C., Forsman J., Hassan Z., et al. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice. Exp Hematol 33 (2005) 380-387
60. Meresse V., Hartmann O., Vassal G., et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 10 (1992) 135-141
61. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 8 (2002) 468-476
62. Bornhauser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102 (2003) 820-826
63. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104 (2004) 857-864